Enzo Biochem And Flagship Biosciences Partner To Provide Tissue-Based Companion Diagnostics Offering Complete Solution For In Situ Hybridization Development To Pharmaceutical Companies
Enzo Biochem Inc. (NYSE:ENZ) and
Flagship Biosciences LLC, of
Boulder, CO, today announced a partnership in tissue-based companion
diagnostics that will enable personalized diagnosis and treatment of
Enzo Biochem Inc. (NYSE:ENZ) and Flagship Biosciences LLC, of Boulder, CO, today announced a partnership in tissue-based companion diagnostics that will enable personalized diagnosis and treatment of disease. The firms are working jointly with pharmaceutical clients that require an independent complete solution to the delivery of an insitu hybridization (ISH) companion diagnostic, which ultimately could have a major impact on drug development. The partnership brings together the strengths of Enzo, a pioneer in molecular diagnostics, and Flagship Biosciences, a leader in the use of quantitative tissue profiling for the development of companion diagnostics products. Flagship Biosciences’ expertise is in pathology, image analysis, cancer biology and regulated tissue-based assays, currently utilized by over 100 pharmaceutical and biotech firms in characterizing both diagnostic and therapeutic antibodies in drug development. The partnership is based on the application of Enzo’s technology, reagents, and protocols (ISH) and analysis of nucleic acid in tissue which is being combined with Flagship’s software imaging and histopathology techniques to give a comprehensive package for pharmaceutical development. Pharmaceutical and biotech companies increasingly include tissue analysis assays in their strategies for companion diagnostics. The companion diagnostics development process is highly regulated, and must be staged in parallel with therapeutic development. A successful ISH companion diagnostic program requires both an antibody/probe product or kit manufactured for use in a clinical environment, and a development team that can characterize the performance and testing environment. Between Enzo and Flagship, pharmaceutical clients will be provided with a complete service for both the nucleic acid product and the companion diagnostics development and image analysis quantization. Enzo today is currently providing a range of products and services for gene expression and chromosomal analysis. Areas of focus include women’s health and the identification of viral genes. Enzo Biochem is leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous approaches. Enzo utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care. Underpinning the Company’s products and technologies is an extensive intellectual property portfolio, with patent coverage across a number of key enabling technologies.